Viracta Therapeutics Inc (NASDAQ:VIRX) announced final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma.
- The data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting.
- Nana-val was well tolerated and demonstrated activity with complete responses observed across multiple EBV+ lymphoma subtypes and a median duration of response of 10.4 months.
- As of the October 28 data cutoff, 55 patients were enrolled.
- Nana-val was generally well tolerated with reversible low-grade toxicities.
- The most commonly observed treatment-emergent adverse events were reversible cytopenias, low-grade creatinine elevations, and gastrointestinal symptoms.
- Among evaluable patients (n=43), an overall response rate of 40% was observed across all lymphoma subtypes.
- Clinical Benefit Rate (CBR) was 56%.
- The median duration of response was 10.4 months, with three patients achieving responses with durations over two years.
- Last month, Viracta secured a $50 million credit facility from Silicon Valley Bank and Oxford Finance.
- Price Action: VIRX shares are are down 5.71% at $3.96 during the market session on the last check Monday.
- Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.
